200 TECHNOLOGY SQUARE, CAMBRIDGE, MA
Annual Report to Security Holders
Moderna Enters $950 Million Settlement Agreement with Arbutus/Genevant
Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Reports Productive Year in 2025 with Multiple Regulatory Approvals
Moderna Enters $1.5 Billion Credit and Guaranty Agreement
Analyst Day Highlights Pipeline Progress and Business Strategy Updates
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
SC TO-I
Tender Offer Statement by Issuer
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Tender Offer Statement by Issuer
Submission Upload
Correspondence